

/N THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

International Application No. : PCT/EP99/09842
 International Filing Date : December 11, 1999
 U.S. Serial No. : 09/868,098
 Deposit Date U.S. Nat'l Phase : June 14, 2001
 Priority Date(s) Claimed : December 19, 1998
 Applicant(s) : Beate DIEFENBACH et al.
 Title: $\alpha\text{v}\beta_6$ INTEGRIN INHIBITORS

**RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS
 UNDER 35 U.S.C. § 371**

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 11213-1450

Sir:


In response to the Notification of Missing Requirements dated September 8, 2003:

- ☐ Attached is a Declaration and Power of Attorney in compliance with 37 CFR § 1.53 along with the late filing surcharge of \$65.00/\$130.00
- ☐ Applicant(s) include an executed assignment and Recordation Form Cover Sheet with the recordation fee of \$40.00 (Check No.).
- ☒ Attached is a copy of the Notification of Missing Requirements.
- ☐ Applicant(s) request that the time for taking action in this case be extended pursuant to 37 CFR 1.136(a) for a period of one/two/three/four/five month(s) along with the fee of \$110.00/\$410.00/\$930.00/\$1450.00/\$1970.00.
- ☐ Applicant(s) are entitled to small entity status.
- ☐ Attached is a verified English translation of the PCT publication along with the fee of \$130.00.
- ☒ Attached is the sequence listing in CFR.
- ☐ Applicant(s) include the extra claims fee of \$ for claims in excess of 20 \$18/\$9 per additional claim, for independent claims in excess of 3 \$84/\$42 per additional claim, and/or \$280 for multiple dependent claims.
- ☒ Applicants affirm that the attached paper and disk versions of the sequence listing are identical and do not contain new matter.

- ☐ Attached is an Application Data Sheet (ADS).
- ☐ Attached are the substitute drawings as required.

Attached is a check in the amount of \$. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402.

Respectfully submitted,



Anthony J. Zelano
Registration No. 27,969
Attorney for Applicants

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703)243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2251

Date: October 29, 2003



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

SEP 12 2003

U.S. APPLICATION NUMBER NO.

09/868,098

FIRST NAMED APPLICANT

Beate Diefenbach

ATTY. DOCKET NO.

MERCK 2251

INTERNATIONAL APPLICATION NO.

PCT/EP99/09842

I.A. FILING DATE

12/11/1999


PRIORITY DATE

23599

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
2200 CLARENDON BLVD.
SUITE 1400
ARLINGTON, VA 22201

CONFIRMATION NO. 5446

1 FORMALITIES LETTER



000000010809137*

Date Mailed: 09/08/2003

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e) and PCT Rule 13ter.1(a)(ii).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

CASE _____

ACTION _____

DUE DATE 11/8/03

MAMIE P PERSON

Telephone: (703) 305-3737

PART 1 - ATTORNEY/APPLICANT COPY

*SKT-1
9/12/03
[Signature]*

U.S. APPLICATION NUMBER NO. 09/868,098	INTERNATIONAL APPLICATION NO. PCT/EP99/09842	ATTY. DOCKET NO. MERCK 2251
---	---	--------------------------------

FORM PCT/DO/EO/922 (371 Formalities Notice)